

CLINICAL SUMMARY



Comparison of EndoPredict and EPclin with Oncotype DX® recurrence score for prediction of risk of distant recurrence after endocrine therapy

Buus R. et al., JNCI J Natl Cancer Inst (2016) 108(11): djw149

Introduction

Decisions on the use of adjuvant chemotherapy in estrogen receptor (ER) positive, HER2-negative primary breast cancer are guided by the risk of distant recurrence. EndoPredict Breast Cancer Prognostic Test and Oncotype DX® are prognostic gene expression tests used for estimating distant recurrence risk.

EndoPredict provides prognostic information from a molecular signature combined with tumor size and nodal status (EPclin Score). Oncotype DX provides prognostic information only from a molecular signature (Recurrence Score- RS).

Study aim

The aims of the study were to:

- Validate the prognostic value of EPclin in the TransATAC study
- Compare the prognostic abilities of EPclin with that of RS

Clinical cohort description

Cohort	Treatment	Primary endpoint	Number of women	Median follow-up
• Primary breast cancer • ER+, HER2- • Node positive and negative • Postmenopausal	5 years endocrinotherapy only	Distant relapse-free survival	928	10 years


Results

EPclin:

- Is highly prognostic for all patients across 10 years, and in the node negative and positive subgroups
- Accurately predicts early (0-5 years) and late (5-10 years) metastasis
- Identifies a large low risk group with excellent outcomes after 10 years without chemotherapy


EPclin provides substantially more prognostic information than RS

EPclin and RS prognostic ability to detect metastasis




*The χ^2 -value is a standard statistic for prognostic power that is used to compare prognostic accuracy of different tests. The greater the χ^2 -value, the better is the prognostic power of a test. The χ^2 -value reflects the prognostic power of the continuous score independent from cutoff values.


The classification by EPclin aligns more closely with the patient outcomes



EPclin outperforms RS in accurately identifying low risk patients



EPclin identifies 9% more patients at low risk than RS with excellent outcomes at 10 years



EPclin shows significantly less 10-year recurrence rates than RS in the low risk group (5.0% for EPclin vs 25.1% for RS)

Conclusions

- EPclin provides more prognostic information than RS, particularly for late metastasis.
- EPclin provides superior risk stratification compared to RS.
- The superior performance of EPclin compared with RS is due to a superior molecular component that predicts late events (years 5-10) and the inclusion of clinical variables (nodal status and tumor size) in EPclin.

Bottom line

EndoPredict identifies more accurately low risk patients with a low recurrence rate than Oncotype DX



Eurobio Scientific GmbH
Nattermannallee 1, Building S19
50829 Köln
Germany

info-INT@eurobio-scientific.de
www.eurobio-scientific.de



Eurobio Scientific, the Eurobio Scientific logo, EndoPredict and the EndoPredict logo are either trademarks or registered trademarks of Eurobio Scientific. ©2024 Eurobio Scientific GmbH

ENDO_MD_CS_BUUS_COMP_09_24_EN

